logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11376326 B1

PDFFull Text
Date of Patent:
Jul. 05, 2022

Filed:

Jun. 30, 2016

Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective

Applicant:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Inventors:

Toshihiko Ohtomo, Tokyo, JP;

Takayoshi Tanaka, Tokyo, JP;

Yasuo Sugitani, Tokyo, JP;

Assignee:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Attorney:

Nixon & Vanderhye P.C.

Primary Examiner:

Lisa V Cook

Int. Cl.
CPC ...
G01N 31/00 (2006.01); G01N 33/53 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C12Q 1/02 (2006.01); G01N 33/68 (2006.01); G01N 33/574 (2006.01); A61K 31/44 (2006.01); A61K 45/00 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 31/44 (2013.01); A61K 39/395 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12Q 1/02 (2013.01); G01N 33/574 (2013.01); G01N 33/57438 (2013.01); G01N 33/68 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C07K 16/18 (2013.01); C07K 16/46 (2013.01); G01N 2800/50 (2013.01); G01N 2800/7028 (2013.01);
Abstract

The present invention provides a method for determining the efficacy of a GPC3-targeting therapeutic agent for a liver cancer patient and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective. The present invention provides, for example, a method for determining that a GPC3-targeting therapeutic agent is effective when the expression level of GPC3 per tumor cell is a predetermined value, and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective.

Find Patent Forward Citations

Loading…